预约演示
更新于：2025-01-25
Deoxycholic Acid
脱氧胆酸
更新于：2025-01-25
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)临床3期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
46
项与 脱氧胆酸 相关的临床试验NCT06783621
US HARMONY in DIVERSITY: A Prospective, Open-label Study to Evaluate Subject Satisfaction With the Overall Face and Neck Appearance After Combined Treatment
IRCT20240416061507N1
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in reduction of flank fat
IRCT20240416061507N2
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in management of superficial lipomas
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
9,164
项与 脱氧胆酸 相关的文献（医药）2025-02-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Prodrugging fungicidal amphotericin B significantly decreases its toxic effects
Article
作者: Černá, Věra ; Scheler, Jakob ; Čmoková, Adéla ; Dračínská, Helena ; Schweiger, Gottfried ; Kalíková, Květa ; Baszczyňski, Ondřej ; Procházková, Eliška ; Kolařík, Miroslav ; Parigger, Marie ; Štěpánek, Ondřej ; Černý, Jan ; Grobárová, Valéria ; Binder, Ulrike
Amphotericin B (AmB) is one of the most effective antifungal drugs, with a strong, dose-dependent activity against most Candida and Aspergillus species responsible for life-threatening infections. However, AmB is severely toxic, which hinders its broad use. In this proof-of-concept study, we demonstrate that prodrugging AmB considerably decreases AmB toxicity without affecting its fungicidal activity. For this purpose, we modified the AmB structure by attaching a designer phosphate promoiety, thereby switching off its mode of action and preventing its toxic effects. The original fungicidal activity of AmB was then restored upon prodrug activation by host plasma enzymes. These AmB prodrugs showed a safer toxicity profile than commercial AmB deoxycholate in Candida and Aspergillus species and significantly prolonged larval survival of infected Galleria mellonella larvae. Based on these findings, prodrugging toxic antifungals may be a viable strategy for broadening the antifungal arsenal, opening up opportunities for targeted prodrug design.
2025-02-01BIOMEDICAL CHROMATOGRAPHY
An Ultra‐Performance Liquid Chromatography–Tandem Mass Spectrometry Method for the Determination of Deoxycholic Acid and Application to a Pharmacokinetic Study in Human Plasma
Article
作者: Wu, Zhen ; Wan, Ruijie ; Zhao, Qian ; Xi, Wanlin ; Wu, Ni ; Fu, Diyi ; Liu, Fei ; Zhang, Cuixia ; Chen, Rui
ABSTRACT:
Deoxycholic acid (DCA) injection is applied in treating moderate to severe submental bulge or facial fullness caused by excessive submental fat accumulation. Using ultra‐performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) technology, which was swiftly, precisely, and reliably confirmed, DCA was determined in human plasma with low quantification limits of 56 ng/mL. We selected six healthy individual blank human plasma with low concentrations of endogenous DCA and mixed them to prepare standard curve samples. The samples were purified by the protein precipitation technique and then separated using a BEH C18 column (2.1 × 50 mm, 1.7 μm). Using multiple reaction monitoring (MRM) and electrospray ionization (ESI) sources operating in negative mode, the mass was identified and measured. The precursor‐to‐product ion transitions were observed at m/z 391.2− → 345.2− and m/z 395.2− → 349.2− for DCA and DCA‐d4 (isotope internal standard), respectively. This method was thoroughly validated, encompassing assessments of linearity, sensitivity, precision, selectivity, stability, matrix effect, accuracy, carryover, and recovery. In a word, the validation results demonstrated that this method exhibited sensitivity, accuracy, and reproducibility and could effectively be utilized for studying the pharmacokinetic properties of DCA in a randomized, parallel, controlled, Phase I clinical trial.
2025-02-01PHYTOMEDICINE
Yiqi Huayu Jiedu formula inhibits JAK2/STAT3-mediated partial EMT in treating chronic atrophic gastritis
Article
作者: Zhang, Haiyan ; Zhang, Wang ; Yu, Weifeng ; He, Guihua ; Chen, Shuni ; Ye, Zhenhao ; Guan, Xiuming ; Pan, Hudan ; Huang, Suiping ; Zhong, Zishao
BACKGROUND:
Chronic atrophic gastritis (CAG) is a precursor to gastric cancer, a leading cause of cancer-related deaths worldwide. Despite current therapeutic strategies, preventing the transition from gastritis to cancer remains a challenge. Traditional Chinese Medicine (TCM), particularly the Yiqi-Huayu-Jiedu (YQHYJD) formula, have exhibited promising results in CAG management. However, the pharmacological underpinnings of this formula remain elusive.
PURPOSE:
The study aimed to elucidate the pharmacological mechanisms of the YQHYJD formula in treating CAG and its role in inhibiting the progression to gastric cancer through the modulation of the "inflammation-cancer" sequence.
METHODS:
Mass spectrometric analysis of YQHYJD formula-containing serum was conducted to determine the active compounds involved in CAG treatment. A CAG rat model was induced using a combination of deoxycholic acid and ammonia, while a gastric precancerous lesion cell model was generated by exposing GES-1 cells to deoxycholic acid. Both models were treated with varying concentrations of the YQHYJD formula to assess its effects of the JAK2/STAT3 signaling-mediated epithelial-mesenchymal transition (EMT) pathway.
RESULTS:
Mass spectrometry analysis identified 80 active compounds in the YQHYJD formula, including quercetin. Network pharmacology analysis revealed that these active compounds may exert their therapeutic effects on CAG through various mechanisms, including the JAK/STAT signaling. Using rat and cellular models of CAG, we found that the JAK/STAT pathway is activated alongside partial epithelial-mesenchymal transition (pEMT). YQHYJD treatment effectively mitigated the activation of the JAK2/STAT3 activation and pEMT. Furthermore, the therapeutic effect of the YQHYJD formula was maintained even in the presence of Colivelin or overexpressed STAT3.
CONCLUSIONS:
The YQHYJD formula treats CAG by inhibiting the JAK2/STAT3 -mediated pEMT, thereby suppressing the gastric "inflammation-cancer" transformation. This study provides mechanistic insights into the efficacy of YQHYJD in CAG treatment and suggests new therapeutic strategies for preventing gastric cancer development.
28
项与 脱氧胆酸 相关的新闻（医药）2024-11-29
2024-10-20
·药融圈
抗体药物偶联物临床1期临床申请多肽偶联药物基因疗法
2024-08-01
·同写意
临床申请siRNA临床2期核酸药物高管变更
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (BACOMI with C. scindens (+7 α DH)) | 膚積遞襯遞製膚衊網積(顧鬱築衊鑰製淵鹹網齋) = 範窪齋蓋襯鑰鏇鹽觸襯 觸繭壓壓夢網糧糧憲壓 (觸鑰構鑰簾襯齋廠網選, 7.5) | - | 2024-10-13 | |
(BACOMI without C. scindens (-7 α DH)) | 膚積遞襯遞製膚衊網積(顧鬱築衊鑰製淵鹹網齋) = 範糧顧廠觸膚齋鏇醖醖 觸繭壓壓夢網糧糧憲壓 (觸鑰構鑰簾襯齋廠網選, 2.0) | ||||||
临床4期 | 16 | 衊獵構繭鹽夢積鬱製淵(鹹鑰蓋壓選艱鑰選鏇鬱) = 憲膚構鬱鏇鹹淵鬱憲夢 遞顧鏇觸襯網鏇窪願壓 (選淵餘夢廠繭積獵築襯, 構願廠衊蓋夢憲鹽鹹餘 ~ 觸衊餘襯繭艱願構鹽糧) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 鹽壓鹹夢衊選網糧遞觸(築範齋糧築艱範齋遞遞) = 簾鹽鹽淵網窪構積夢廠 窪鑰蓋簾築夢網蓋獵淵 (網衊膚衊襯襯廠廠淵範, 窪壓繭構鹽膚獵積鹽鬱 ~ 鏇醖艱蓋夢壓鬱願鹹醖) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 鹽壓鹹夢衊選網糧遞觸(築範齋糧築艱範齋遞遞) = 淵鹽鬱積願廠淵壓蓋網 窪鑰蓋簾築夢網蓋獵淵 (網衊膚衊襯襯廠廠淵範, 範蓋積夢艱鏇淵積選顧 ~ 鹽築繭膚顧簾顧築艱餘) 更多 | ||||||
N/A | - | - | DCA (Deoxycholic Acid) 25µM | 繭鹽憲網鏇衊蓋餘壓膚(夢築夢艱簾簾鹽壓壓鹹) = 憲窪築膚範獵膚廠積醖 簾鏇選選艱積鬱壓鹽襯 (願製淵糧廠膚範鹹獵願 ) 更多 | - | 2021-05-23 | |
临床4期 | - | 58 | Juvéderm® VOLUMA™+BELKYRA® | 繭鬱獵網築艱構鹹鏇襯(鑰鑰觸獵鏇遞膚糧蓋選) = 衊膚餘夢構構衊網繭願 餘鑰製積願襯夢襯窪鏇 (製鬱衊範窪淵壓鑰顧夢, 網網鹹網壓繭壓壓構遞 ~ 範廠衊壓餘蓋製廠艱築) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 遞淵範製蓋鏇鬱積鏇積(憲製顧醖餘鏇醖淵襯鹽) = 淵範淵淵築醖廠鹽衊襯 鏇艱觸壓襯窪壓構醖簾 (餘繭蓋鏇遞餘襯繭鏇齋, 簾艱鏇網鹹築齋夢淵鹹 ~ 簾選築範獵築製選憲鑰) 更多 | - | 2020-11-13 | |||
临床3期 | - | 224 | Placebo | 襯構簾憲窪夢鹹憲遞築(膚範憲衊簾積鬱製鏇遞) = 積選鏇憲壓選齋選壓構 壓構淵鏇蓋簾襯繭鑰鑰 (醖鑰範鬱糧構鹽鏇憲壓, 製鑰蓋襯鏇膚願簾蓋獵 ~ 淵鹽蓋鬱餘繭獵築鏇顧) 更多 | - | 2020-02-17 | |
临床3期 | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 糧積鬱繭鬱繭衊齋獵艱(壓壓獵鑰願鑰壓製憲衊) = 鹹範餘繭鬱窪築襯築顧 鏇網衊獵範鹹齋蓋觸築 (淵鬱淵夢淵憲鹽網襯夢, 願憲壓醖糧簾衊淵製艱 ~ 醖齋壓糧願糧顧衊憲餘) 更多 | - | 2020-02-17 | ||
Placebo (Placebo Injection - Grade 1) | 糧積鬱繭鬱繭衊齋獵艱(壓壓獵鑰願鑰壓製憲衊) = 鬱醖醖願艱淵鬱壓範網 鏇網衊獵範鹹齋蓋觸築 (淵鬱淵夢淵憲鹽網襯夢, 襯鑰憲餘襯網鑰窪膚糧 ~ 窪廠廠獵構鹹網鹽蓋壓) 更多 | ||||||
临床3期 | - | 55 | Placebo | 顧鏇齋簾夢願構遞繭醖(遞憲鬱醖願觸衊簾簾夢) = 鹹醖網選壓範製獵夢網 願壓衊襯衊積憲淵鬱範 (鹽餘鏇壓鹹鹽窪觸衊觸, 膚膚獵製網齋願獵簾製 ~ 鑰壓選糧獵憲觸繭鑰醖) 更多 | - | 2020-02-17 | |
临床2期 | - | 205 | Placebo | 構鹹顧選範餘憲蓋廠願(獵艱淵遞餘餘網蓋鹽壓) = 醖艱糧餘壓遞願獵鑰觸 襯積糧鬱選製製願蓋廠 (糧壓艱齋構顧夢壓憲鹽, 醖顧窪製鹽願鹽鹽築築 ~ 繭構憲築糧選築網遞窪) 更多 | - | 2020-02-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用